| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 1.26 | 51.8% |
| Total Income | 1.26 | 51.8% |
| Expenditure | 13.37 | 0.4% |
| PBT | -13.91 | 48.3% |
| Net Profit | -13.91 | 48.3% |
| OPM | — | |
| NPM | — | |
| EPS | -0.17 | 67.3% |
Lucid Diagnostics Reports Q1 2026 Revenue of $1.3 Million
14 May 2026 · 14 May, 5:37 pm
Summary
Lucid Diagnostics reported first quarter 2026 financial results, with EsoGuard related revenues of $1.3 million. The company processed 3,177 EsoGuard® tests during the quarter. Operating expenses were approximately $13.4 million, including stock-based compensation expenses of $1.4 million. Lucid Diagnostics ended the quarter with $45 million in proforma cash, extending the runway into 2027.
Key Highlights
- 1
Lucid Diagnostics processed 3,177 EsoGuard® tests in Q1 2026.
- 2
The company recognized $1.3 million in EsoGuard® revenue for Q1 2026.
- 3
Lucid Diagnostics ended Q1 2026 with $45 million in proforma cash, extending the runway into 2027.
- 4
The company had a strong presence at Digestive Disease Week (DDW), engaging with the gastroenterology community.
- 5
GAAP net loss attributable to common stockholders was approximately $23.6 million, inclusive of a deemed Preferred Stock dividend of $9.7 million or $(0.17) per common share.
- 6
Non-GAAP adjusted loss for the three months ended March 31, 2026, was approximately $10.5 million or $(0.07) per common share.
Management Comments
Lishan Aklog
M.D.
“Securing Medicare coverage remains our most important pending milestone, and our confidence in a positive outcome has not wavered,” “We continue to build commercial momentum for EsoGuard by generating consistent demand, progressing our Medicare and VA targeting efforts, and expanding engagement with health systems and commercial payors. Together with our strengthened balance sheet, these initiatives have us well-positioned to convert EsoGuard demand to revenue and further accelerate commercialization as Medicare and other key reimbursement milestones are achieved.”
Informational and educational content only. Not investment advice.